The hand-foot syndrome in oncological patients receiving chemotherapy

Ekaterina V. Orlova; T. A Belousova; O. V Grabovskaya; L. Yu Sevidova; A. A Bagirova

doi:10.17816/dv36974

Russian Journal of Skin and Venereal Diseases ›› 2015, Vol. 18 ›› Issue (5) : 21 -25. DOI: 10.17816/dv36974

Articles

research-article

The hand-foot syndrome in oncological patients receiving chemotherapy

Author information +

History +

PDF

Abstract

Side effects of chemotherapy in cancer patients treated by fotemustin are described, manifesting by the hand-foot syndrome - ulcerative necrotic polymorphic dermal angiitis.

Keywords

hand-foot syndrome / chemotherapy / polymorphic dermal angiitis / fotemustin

Cite this article

Download citation ▾

Ekaterina V. Orlova, T. A Belousova, O. V Grabovskaya, L. Yu Sevidova, A. A Bagirova. The hand-foot syndrome in oncological patients receiving chemotherapy. Russian Journal of Skin and Venereal Diseases, 2015, 18(5): 21-25 DOI:10.17816/dv36974

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Beveridge R.A., Kales A.N., Binder R.A., Miller J.A., Virts S.G. Pyridoxine (B6) and amelioration of hand/foot syndrome. Proc. Am. Soc. Clin. Oncol. 1990; 9 (Suppl): 102a.

[2]	Yarbro C.H., Frogge M.H., Goodman M. Cancer symptom management. Sudbury: Jones and Bartlett Publishers; 2004.

[3]	Gabizon A., Goldenhersh M.A., Hubert A., Ingber A., Lotem M., Peretz T., Gabizon A. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch. Dermatol. 2000; 136(12): 1475-80.

[4]	Lorusso D., Di Stefano A., Carone V., Fagotti A., Pisconti S., Scambia G. Pegylated liposomal doxorubicin-related palmarplantar erythrodysesthesia («hand-foot»-syndrome). Ann. Oncol. 2007; 18(7): 1159-64.

[5]	Martschick A., Sehouli J., Patzelt A., Richter H., Jacobi U., Oskay-Ozcelik G., et al. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res. 2009; 29(6): 2307-13.

[6]	Болотина Л.В., Горбунова В.А., Кононенко И.Б., Моисеенко В.М., Орлова Е.В. и др. В сб.: Практические рекомендации по лечению злокачественных опухолей и практические рекомендации по поддерживающей терапии в онкологии. М.: RUSSCO; 2014: 371-4.

[7]	Gressett S.M., Stanford B.L., Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J. Oncol. Pharm. Pract. 2006; 12(3): 131-41.

[8]	Lipworth A.D., Robert C., Zhu A.X. Hand-foot syndrome (handfoot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009; 77(5): 257-71. doi: 10.1159/000258880.

[9]	Kara I.O., Sahin B., Erkisi M. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast. 2006; 15(3): 414-24.

[10]	Mangili G., Petrone M., Gentile C., De Marzi P., Vigano R., Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: The role of regional cooling. Gynecol. Oncol. 2008; 108(2): 332-35.